spironolactone has been researched along with Hypokalemic Periodic Paralysis in 6 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Hypokalemic Periodic Paralysis: An autosomal dominant familial disorder characterized by recurrent episodes of skeletal muscle weakness associated with falls in serum potassium levels. The condition usually presents in the first or second decade of life with attacks of trunk and leg paresis during sleep or shortly after awakening. Symptoms may persist for hours to days and generally are precipitated by exercise or a meal high in carbohydrates. (Adams et al., Principles of Neurology, 6th ed, p1483)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Renovascular hypertension is one of the common causes of secondary hypertension." | 1.48 | Unilateral renal artery stenosis presenting as acute flaccid paralysis: a rare presentation. ( Banerjee, S; Garg, K; Rajput, R; Singh, PK, 2018) |
| "Hypokalemic periodic paralysis (HOKPP) is a rare disorder characterized by episodic muscle weakness with hypokalemia." | 1.36 | Severe respiratory phenotype caused by a de novo Arg528Gly mutation in the CACNA1S gene in a patient with hypokalemic periodic paralysis. ( Kil, TH; Kim, JB, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, PK | 1 |
| Rajput, R | 1 |
| Banerjee, S | 1 |
| Garg, K | 1 |
| Weber, MA | 1 |
| Jurkat-Rott, K | 1 |
| Lerche, H | 1 |
| Lehmann-Horn, F | 1 |
| Tran, HA | 1 |
| Reeves, GE | 1 |
| Kil, TH | 1 |
| Kim, JB | 2 |
| Lee, KY | 1 |
| Hur, JK | 1 |
| Nemoto, H | 1 |
| Kurihara, T | 1 |
1 review available for spironolactone and Hypokalemic Periodic Paralysis
| Article | Year |
|---|---|
[Periodic paralysis secondary to urinary or gastrointestinal potassium loss].
Topics: Animals; Diagnosis, Differential; Diarrhea; Digestive System; Drug Therapy, Combination; Humans; Hyp | 2001 |
5 other studies available for spironolactone and Hypokalemic Periodic Paralysis
| Article | Year |
|---|---|
Unilateral renal artery stenosis presenting as acute flaccid paralysis: a rare presentation.
Topics: Antihypertensive Agents; Diagnosis, Differential; Humans; Hyperaldosteronism; Hypertension, Renovasc | 2018 |
Strength and muscle structure preserved during long-term therapy in a patient with hypokalemic periodic paralysis (Cav1.1-R1239G).
Topics: Adult; Calcium Channels, L-Type; Female; Humans; Hypokalemic Periodic Paralysis; Mineralocorticoid R | 2019 |
Hepatitis C infection and thyrotoxic periodic paralysis--a novel use of an old drug.
Topics: Diuretics; Female; Hepatitis C; Humans; Hypokalemic Periodic Paralysis; Male; Middle Aged; Spironola | 2008 |
Severe respiratory phenotype caused by a de novo Arg528Gly mutation in the CACNA1S gene in a patient with hypokalemic periodic paralysis.
Topics: Adolescent; Amiloride; Amino Acid Substitution; Arginine; Calcium Channels; Calcium Channels, L-Type | 2010 |
A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G).
Topics: Acetazolamide; Adolescent; Arginine; Calcium Channels; Calcium Channels, L-Type; Codon; Exons; Famil | 2005 |